Radiotherapy of bronchogenic carcinoma: analysis of a treatment schedule designed for use with hyperbaric oxygen. [/sup 60/Co]

Sause, W T; Sweeney, R A; Plenk, H P; Thomson, J W

doi:10.1148/radiology.140.1.7244227

Title: Radiotherapy of bronchogenic carcinoma: analysis of a treatment schedule designed for use with hyperbaric oxygen. [/sup 60/Co]

Full Record
Other Related Research

Abstract

All cases of bronchogenic carcinoma treated with curative intent over an eight-year period were reviewed. Most were treated with 12 x 400 rad in 32 days using /sup 60/Co, a schedule designed to optimize the radiation-sensitizing properties of hyperbaric oxygen. While O/sub 2/ gave no obvious benefit, overall four-year survival was 10.6% and that of patients with good prognostic indicators was 18%. No radiation myelitis was observed. This protocol delivers an adequate tumor dose and appears to be tolerated well by most patients.

Authors:: Sause, W T; Sweeney, R A; Plenk, H P; Thomson, J W

Publication Date:: Wed Jul 01 00:00:00 EDT 1981

Research Org.:: LDS Hospital, Salt Lake City, UT

OSTI Identifier:: 6120491

Resource Type:: Journal Article

Journal Name:: Radiology; (United States)

Additional Journal Information:: Journal Volume: 140:1

Country of Publication:: United States

Language:: English

Subject:: 63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.; 62 RADIOLOGY AND NUCLEAR MEDICINE; LUNGS; BIOLOGICAL RADIATION EFFECTS; OXYGEN; RADIOSENSITIVITY EFFECTS; PNEUMONITIS; RADIOINDUCTION; RADIOTHERAPY; SIDE EFFECTS; CARCINOMAS; COBALT 60; FRACTIONATED IRRADIATION; GAMMA RADIATION; SURVIVAL TIME; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BIOLOGICAL EFFECTS; BODY; COBALT ISOTOPES; DISEASES; ELECTROMAGNETIC RADIATION; ELEMENTS; INTERMEDIATE MASS NUCLEI; INTERNAL CONVERSION RADIOISOTOPES; IONIZING RADIATIONS; IRRADIATION; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; MEDICINE; MINUTES LIVING RADIOISOTOPES; NEOPLASMS; NONMETALS; NUCLEAR MEDICINE; NUCLEI; ODD-ODD NUCLEI; ORGANS; RADIATION EFFECTS; RADIATIONS; RADIOISOTOPES; RADIOLOGY; RESPIRATORY SYSTEM; THERAPY; YEARS LIVING RADIOISOTOPES; 560151* - Radiation Effects on Animals- Man; 550603 - Medicine- External Radiation in Therapy- (1980-)

Citation Formats


                    Sause, W T, Sweeney, R A, Plenk, H P, and Thomson, J W. Radiotherapy of bronchogenic carcinoma: analysis of a treatment schedule designed for use with hyperbaric oxygen. [/sup 60/Co].  United States: N. p., 1981. 
        Web.  doi:10.1148/radiology.140.1.7244227.

Copy to clipboard


                    Sause, W T, Sweeney, R A, Plenk, H P, & Thomson, J W. Radiotherapy of bronchogenic carcinoma: analysis of a treatment schedule designed for use with hyperbaric oxygen. [/sup 60/Co].  United States.  https://doi.org/10.1148/radiology.140.1.7244227

Copy to clipboard


                    Sause, W T, Sweeney, R A, Plenk, H P, and Thomson, J W. 1981.  
        "Radiotherapy of bronchogenic carcinoma: analysis of a treatment schedule designed for use with hyperbaric oxygen. [/sup 60/Co]".  United States.  https://doi.org/10.1148/radiology.140.1.7244227.

Copy to clipboard


                    
@article{osti_6120491,

  title        = {Radiotherapy of bronchogenic carcinoma: analysis of a treatment schedule designed for use with hyperbaric oxygen. [/sup 60/Co]},

  author       = {Sause, W T and Sweeney, R A and Plenk, H P and Thomson, J W},

  abstractNote = {All cases of bronchogenic carcinoma treated with curative intent over an eight-year period were reviewed. Most were treated with 12 x 400 rad in 32 days using /sup 60/Co, a schedule designed to optimize the radiation-sensitizing properties of hyperbaric oxygen. While O/sub 2/ gave no obvious benefit, overall four-year survival was 10.6% and that of patients with good prognostic indicators was 18%. No radiation myelitis was observed. This protocol delivers an adequate tumor dose and appears to be tolerated well by most patients.},

  doi          = {10.1148/radiology.140.1.7244227},

  url          = {https://www.osti.gov/biblio/6120491},
  journal      = {Radiology; (United States)},
number       = ,

  volume       = 140:1,

  place        = {United States},

  year         = {Wed Jul 01 00:00:00 EDT 1981},

  month        = {Wed Jul 01 00:00:00 EDT 1981}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1148/radiology.140.1.7244227

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Radiation therapy of head and neck tumors: a randomized study of treatment in air vs treatment in hyperbaric oxygen

Conference Sause, W; Plenk, H - Int. J. Radiat. Oncol., Biol. Phys.; (United States)

A randomized study of squamous cell carcinoma of the head and neck, with the exception of T/sub 1/ vocal cord lesions, compared 23 patients who were treated in air with doses of 250 rad four times a week to 6250 rad, to 21 patients who were treated at three atmospheres of hyperbaric oxygen with 12 x 400-rad fractions in approximately 32 days. Distribution by anatomic site and age was comparable. Distribution by stage was in favor of the air group since five Stage I patients were found in the air group but none in the hyperbaric oxygen group. The sexmore »« less
Sequential radiotherapy and adriamycin in the management of bronchogenic carcinoma: the question of additive toxicity

Conference Ruckdeschel, J; Baxter, D; McKneally, M; ... - Int. J. Radiat. Oncol., Biol. Phys.; (United States)

Intrapleural immunotherapy, radiotherapy and chemotherapy were employed in that sequence in 22 patients with Stage III non-oat cell bronchogenic carcinoma confined to the thorax. Seven patients received intrapleural BCG in a pilot study and 15 were randomized between intrapleural BCG and intrapleural saline. Isoniazid was begun on day 14 and irradiation (3000 rad in 10 fractions) to the primary lesion, mediastinum and ipsilateral supraclavicular nodes was started on day 21. One to two weeks following irradiation, CAMP chemotherapy was initiated (Cyclophosphamide 300 mg/M/sup 2/ iv, d. 1,8; Adriamycin 20 mg/M/sup 2/ iv, d. 1,8; Methotrexate 15 mg/M/sup 2/ iv, d.more »« less
Prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung

Journal Article Perez, C; Stanley, K; Rubin, P; ... - Cancer; (United States)

Analysis is presented of a prospective randomized study involving 365 patients with histologically proven unresectable non-oat-cell carcinoma of the lung treated with deffinitive radiotherapy. The patients were radomized to one of four treatment regimens: 4000 rad split course, or 4000, 5000, or 6000-rad continuous courses in five fractions per week. Ninety to 100 patients were accessioned to each group. The one-year survival rate is 50% and the two-year survival rate, 25%. The patients treated with the split course have the lowest survival rate in comparison with the other groups. The complete and partial local regression of tumor was 49% inmore »« less
Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study

Journal Article Trovo, M; Minatel, E; Veronesi, A; ... - Cancer (Philadelphia); (USA)

Between June 1980 and December 1983, 111 patients with inoperable epidermoid bronchogenic carcinoma (limited disease) were entered into a randomized trial comparing radiotherapy alone versus radiotherapy and combination chemotherapy with cyclophosphamide, Adriamycin (doxorubicin), methotrexate, and procarbazine. Thirty-five of 62 (56.4%) patients treated with 4500 rad in 15 fractions in 3 weeks and 19 of 49 (38.8%) patients treated with the same radiation treatment and chemotherapy had an objective response. The difference in response rate was not significant (P = 0.900). Median time to progression was 5.9 and 7.02 months, respectively, for the radiation treatment and the combined treatment. Median survivalmore »« less
https://doi.org/10.1002/1097-0142(19900201)65:3<400::AID-CNCR2820650304>3.0.CO;2-H
Role of Radiotherapy in the Treatment of Cervical Lymph Node Metastases From an Unknown Primary Site: Retrospective Analysis of 113 Patients

Journal Article Beldi, Debora; Jereczek-Fossa, Barbara; D'Onofrio, Alberto; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: The management of patients with cervical lymph-node metastases from unknown primary site (UPS) remains a matter of discussion. This study aimed to analyze the results and prognostic factors in a series of patients treated with radiotherapy. Methods and Materials: Data from 113 patients who presented with cervical lymph nodes metastases from UPS treated from 1980 to 2004 were reviewed. Eighty-seven patients (77.0%) were squamous cell carcinoma (SCC). Ninety-one patients were treated with curative and 22 with palliative intent. Fifty-nine of 113 patients (52.2%) received surgery followed by radiotherapy and 54 of 113 (47.8%) received radiotherapy alone. Radiotherapy was deliveredmore »« less
https://doi.org/10.1016/j.ijrobp.2007.04.039

Similar Records